7 Multibagger Ideas: Quality Small-Cap Stocks (2026)
These stocks have it in their DNA to become multibaggers.
New to The Atomic Moat? If you want more multibagger lists such as this sent to your inbox, join 1,500+ other investors below.
First, let’s kill the word
“Multibagger” is a clickbait word. I know it, you know it, and the algorithm knows it. So let me defuse it before we go any further.
A multibagger is a business that compounds its value at a high rate, held for a long time. That’s it. The multiple is arithmetic, not magic.
Watch how fast the arithmetic runs. A business that compounds intrinsic value at 20% a year turns into roughly a 6-bagger in ten years, a 15-bagger in fifteen, and a 95-bagger in twenty-five.
Berkshire became one of the great 100-baggers of all time the boring way: it compounded at around 20% for sixty years. Buffett bought predictable, wonderful businesses at fair prices and then did the hardest thing in investing, which is nothing.
“The big money is not in the buying and the selling, but in the waiting.” — Charlie Munger
So when I screen for “multibaggers,” I am really screening for three ingredients, and I want you to use the same three on every name below:
A durable compounding engine. A high return on capital that the business can actually reinvest, not just earn once. The return on the next dollar is what matters, not the average return on the dollars already spent.
A long runway. Room to keep redeploying cash at that high rate for a decade or two. A brilliant business with no room to grow is a lovely dividend stock and a poor wealth-builder.
Hold-ability. Enough predictability that you can sit through the three 50% drawdowns every one of these will hand you without selling at the bottom. This is the ingredient everyone ignores, and it is the one that actually decides whether you collect the multiple or just admire it from the exit.
There is a fourth thing that turns a good return into a spectacular one, and it is not what most people think.
Total return comes from two engines: growth in the business, and a change in the valuation multiple.
For a real long-run winner the growth does the heavy lifting, tens of times over. The multiple re-rating is a 2x to 3x kicker on top. That kicker is not bargain-hunting. It is the market slowly admitting it had the wrong label on a business, and the day it admits that is the day your thesis pays you twice.
One last thing about where these live. A famous study of 104 stocks that returned more than 350% over five years found the winners clustered in Sweden, the UK, Germany, Norway, and Australia, with thin analyst coverage, and 84% of them started under $2 billion in market cap. Small, neglected, developed-market businesses are the pond.
Five of the seven names below are fishing in exactly that water. Two are not, and I will tell you which.
Disclaimer: All content is for informational and entertainment purposes only and does not constitute financial advice.
The seven
These come in three flavours.
The compounding machines own the process of getting bigger. The fallen quality names are good businesses the market has thrown out with the bathwater. The asymmetric bets are smaller, spicier, and more binary, where the upside is large and so is the way you can be wrong.
Let’s get to it.
1. Teqnion (TEQ)
Building something for the next 100 years
What it is
Teqnion is a Swedish serial acquirer. It buys small, profitable, gloriously dull industrial companies, the kind that make connectors, transformers, lab equipment, and indication systems for military practice shooting, and then it leaves them alone to keep doing what they were already good at. Founder and CEO Johan Steene talks openly about building a company that lasts a hundred years, and he runs it like someone who means it: decentralised, cash-focused, allergic to head-office empire-building.
The numbers today
The stock trades around SEK 158, for a market cap near SEK 2.5 billion, which is about $255 million. Full-year 2025 revenue was roughly SEK 1.8 billion with net income near SEK 98 million, putting the shares around 28 times earnings. There is no dividend, by design. Every krona that comes in goes back out to buy the next business. The stock is up modestly over the past year and has spent twelve months bouncing between SEK 136 and SEK 189.
The runway
This is the part that matters. There are tens of thousands of small, owner-run industrial niche businesses across the Nordics and Europe whose founders will eventually want to retire and sell to a good home. Teqnion is a rounding error against that universe. A serial acquirer this size does not have a TAM problem; it has a “can we keep finding good deals and not overpay” problem. The engine is the acquisition process itself: the culture, the discipline, the decentralisation. The product could change entirely and the moat would still be there.
Why it could be a multibagger
The model is proven. Constellation Software, Lifco, Lagercrantz, and Indutrade all turned the same playbook into double-digit-to-twenty-percent per-share compounding for decades. Teqnion is early on that curve and small enough that its size edge is real, which is exactly the combination the data says you want. If Steene keeps buying well, a small base compounding in the high teens for twenty years is the whole multibagger story, and it requires no heroics.
What has to go right, and what could break it
A serial acquirer is only as good as its discipline. The headline P/E looks pricey because acquisition goodwill sits on the balance sheet and drags reported returns down; the honest way to judge Teqnion is the return on tangible capital and the return on each new acquisition, and that is the thing to watch every year. The risks are the obvious ones for the model: overpaying as it scales, diluting shareholders if it issues too many shares to fund deals, and the simple fact that the businesses underneath are lower-margin industrials, not asset-light software. None of that is fatal. All of it is worth watching.
2. Röko (ROKO B)
Lifco 2.0, run by the man who built Lifco
What it is
Röko is the same serial-acquirer idea as Teqnion, scaled up and run by serious pedigree. It was founded in 2019 and chaired by Fredrik Karlsson, the former CEO who compounded Lifco into one of Europe’s great acquisition machines. Röko buys majority stakes in profitable European niche leaders, mostly businesses with EBITA between two and ten million euros, and keeps them forever under a decentralised model that preserves each company’s name and independence. It listed its B shares in Stockholm in March 2025.
The numbers today
The stock trades around SEK 1,900, for a market cap near SEK 28 billion, which is roughly $2.9 billion. That makes Röko comfortably the largest name on this list, and I want to be straight about that: at this size it is not a small cap, and it does not get my pure small-cap edge. It trades around 37 times earnings. Net sales were about SEK 6.2 billion for 2024, with adjusted EBITA margins around 20%, and in the first quarter of 2026 it grew organic sales 6% and total sales 9%, with three more acquisitions closed. It has done over thirty platform deals since inception.
The runway
Same answer as Teqnion, just with deeper pockets and a wider net across the UK, the Nordics, the Netherlands, the US, and beyond. The European long tail of family-owned niche businesses is effectively bottomless relative to even a SEK 28 billion acquirer. The constraint is capital discipline and deal flow, never market size.
Why it could be a multibagger
You are buying a proven operator running a proven playbook with a runway measured in decades. Karlsson has done this before at enormous scale, and the whole point of the perpetual-owner model is that it gets compounding-friendlier as the portfolio diversifies. If Röko sustains high-teens compounding of per-share value over fifteen to twenty years, the math takes care of itself.
What has to go right, and what could break it
The 37x multiple is the honest problem. It already prices in a lot of future success, which means the second engine, the multiple, has less room to help you and more room to hurt you if growth disappoints. The model runs on continuously deploying capital at good returns; the day acquisitions get too expensive or integration slips, the flywheel slows. And it is still young as a public company, so the seasoned track record is shorter than Lifco’s was when it earned its reputation. This is the quality-at-a-full-price name in the group. You are paying up for the pedigree.
3. ChemoMetec (CHEMM)
Selling picks and shovels to the cell-therapy gold rush
What it is
ChemoMetec is a Danish company that makes the NucleoCounter, an instrument that counts cells, and then sells the consumable cassettes and reagents that the instrument eats every time it runs. It is a razor-and-blade business pointed at one of the best end-markets in science: bioprocessing, and the booming world of cell and gene therapy. Crucially, it does not bet on any single drug working. It sells the equipment that every lab in the field needs no matter whose drug wins, which is the cleanest way to own a gold rush.
The numbers today
The stock trades around DKK 315, for a market cap near DKK 5.4 billion, which is about $0.8 billion. It earns roughly DKK 10 per share, so it trades around 31 times earnings. The economics are gorgeous: gross margins around 91%, EBITDA margins around 50%, net cash, and a small dividend. Here is the kicker that makes it interesting right now: the stock is down roughly 72% from its 2021 peak of DKK 1,149, and it has traded between DKK 235 and DKK 804 in the past year alone. Analysts covering it carry an average target up near DKK 640.
The runway
Cell and gene therapy is still early, and every approved therapy and every new manufacturing line needs cell counting as a basic, repeated, non-negotiable step. The recurring consumables grow with the installed base, and the installed base grows with the industry. On top of that, management is now pushing a new “XM” platform and talking about a more software-and-licensing-shaped business over time, which is the kind of pivot that, if it works, re-rates the whole company.
Why it could be a multibagger
Start with a 90%-plus gross margin, net-cash, recurring-consumables compounder. Knock 70% off its price. Add a software transition that could change how the market values it. That is a recipe for both engines firing at once: earnings recovering as the cell-therapy cycle turns, and the multiple expanding as the market re-rates a saturated-looking instrument maker back into a growth compounder.
What has to go right, and what could break it
Even after a brutal de-rating, 31 times earnings is not cheap, so this is not a statistical bargain; it is a quality compounder you are buying at a fair-to-rich price after a fall. The reason it fell is real: the NucleoCounter base started to saturate and growth stalled, which is why the stock got cut in half and then some. The XM platform transition is unproven, and “we are becoming a software company” is a sentence that has humbled many a hardware business. Cell-therapy capital spending is also lumpy. You are betting that the franchise is durable and the next chapter works.
4. Docebo (DCBO)
The AI learning platform the market left for dead
What it is
Docebo runs a cloud learning platform that big companies use to train employees, partners, and customers. Think corporate onboarding, compliance, sales enablement, and customer education, all in one system, increasingly wrapped in AI features like AI-assisted content authoring and an AI-powered search layer. It is a Toronto-based founder business, started by Claudio Erba, that sells to everyone from small businesses to large global enterprises.
The numbers today
The stock trades around $16 on Nasdaq, or about CAD 22 in Toronto, for a market cap near $420 million, which is roughly CAD 575 million. That puts it squarely in small-cap territory. The stand-out fact is the fall: Docebo carried a market cap around CAD-equivalent $1.37 billion in early 2025 and has lost roughly 70% of its value since, on slowing growth and a savage de-rating of unprofitable-looking software. It still converts well and runs with net cash, and its most recent earnings call leaned hard on AI features and enterprise wins.
The runway
Corporate learning and development is a large, sticky, recurring market, and the shift from clunky legacy systems to modern cloud platforms is still playing out. Docebo’s job is to keep moving upmarket into bigger enterprise and public-sector deals, where contracts are larger and churn is lower. If it does, a sub-$500 million company in a multi-billion-dollar market has a long way to run.
Why it could be a multibagger
This is a re-rating story. You have a profitable, net-cash SaaS business trading at a fraction of its former valuation. If enterprise momentum is real and growth stabilises, the path is the classic fallen-quality double: earnings keep growing while the multiple climbs back off the floor. The market has priced Docebo as a melting ice cube. It only needs to prove it is a compounding one.
What has to go right, and what could break it
The learning-management market is competitive and crowded, so Docebo has to keep winning on product, not just price. The bigger question, and the one I weight most, is AI. The same AI that Docebo is using as a feature could, in time, commoditise parts of the content-creation and authoring layer that platforms like this charge for. That is a genuine disruption vector, not a hand-wave, and it is the single thing that could turn a cheap stock into a value trap. The bull case requires Docebo to ride AI as a tailwind rather than be eroded by it. So far it is talking the right game. Talk is not proof.
5. XPEL (XPEL)
The boring film that quietly became a brand
What it is
XPEL makes the clear, self-healing film that gets wrapped onto the front of expensive cars to stop rock chips, plus tinted window film, ceramic coatings, and, increasingly, coloured paint protection film. The genius of the business is not the chemistry, which it largely buys. It is the system around it: a trusted brand, a global network of trained installers, and proprietary DAP software with a vast library of pre-cut patterns so an installer can do a clean job with minimal waste. That software and that network are what keep installers loyal.
The numbers today
The stock trades around $45, for a market cap near $1.2 billion. Revenue was roughly $420 million in 2025, and growth has cooled to the low-to-mid teens, with the most recent quarters up around 11% to 14%. It changes hands around 26 to 30 times earnings. For context on what this business has done, its ten-year compound annual growth rate of the share price has been near 50%, which tells you the kind of run it has already delivered, and also why the bar is now higher.
The runway
Paint protection film is still under-penetrated almost everywhere outside a handful of enthusiast markets. The international story, especially China, where XPEL has taken over its own distribution, plus Europe and emerging markets, is the main growth lever. There is a neat demand tailwind too: surveys of car dealers find the overwhelming majority believe PPF boosts a vehicle’s resale value, which helps pull the product into the new-car channel. New formats like coloured film expand the use case further.
Why it could be a multibagger
A premium brand plus a sticky installer network plus proprietary software, all riding a category that is still early in global adoption, with recurring aftermarket consumption underneath. If XPEL re-accelerates international growth and expands margins as its China integration matures, the business compounds and the modest re-rating from here does the rest.
What has to go right, and what could break it
The honest tension is that XPEL is the most mature growth name here. The hypergrowth years are behind it, US growth is normalising, and at ~28 times earnings you are paying for execution. Competition is real, from 3M to specialist film makers, and the dealer and OEM channels can be fickle. China is both the biggest opportunity and the biggest execution risk. This is a “good business keeps being good” thesis, and the multiple it carries means it has to deliver to pay you.
6. I-Tech (ITECH)
One molecule, the entire world’s ships
What it is
I-Tech is about as pure as an IP-royalty business gets. It owns Selektope, a single molecule that goes into marine antifouling paint and stops barnacles from settling on a ship’s hull. The clever part: it does not poison the barnacle, it briefly switches on a receptor that makes the larva swim away. I-Tech licenses this active ingredient to the big paint makers and collects a royalty on every litre sold. The whole company is about a dozen people in Sweden sitting on top of a patent and a regulatory approval.
The numbers today
The stock trades around SEK 84, for a market cap near SEK 1.0 billion, which is roughly $105 million, the smallest name on this list by a wide margin. Revenue is about SEK 175 million, or roughly $18 million, and it has been profitable and dividend-paying. A word of caution on the price: this is a thin micro-cap that just rallied hard, breaking out of a long downtrend with the stock looking overbought, and its twelve-month range runs from around SEK 42 to SEK 125. It moves a lot, on little.
The runway
A fouled hull is a fuel disaster. Marine growth dramatically increases drag, which burns more fuel and emits more carbon, so the value proposition writes itself in a world that cares about both fuel costs and emissions. The total addressable market is the global commercial shipping fleet, which is enormous relative to I-Tech’s tiny revenue. Because this is a royalty, every incremental litre of paint sold drops to the bottom line at extraordinary margins. The growth lever is simple to describe and hard to control: more license agreements with more paint makers, especially in Asia, where the main market sits.
Why it could be a multibagger
This is the textbook asymmetric royalty. A tiny revenue base, near-zero incremental cost on new volume, and a vast end-market. If adoption inflects, if a couple of large Asian coating makers commit, the revenue line can move in a way that a $105 million company simply re-rates around. The shape of the payoff is the appeal: small base times high-margin royalty times a global fleet.
What has to go right, and what could break it
Be honest with yourself about this one. It is a single molecule, which means single points of failure everywhere. The most pressing is regulatory: the EU approval for Selektope has only been extended to the end of 2026, and the full re-registration needs to clear. If it stumbles, it would damage the product’s credibility and could spill over into the all-important Asian market. The business also depends entirely on the paint makers’ decisions to adopt and promote it, which is real customer concentration and a loss of control. And the stock is thin and currently hot. The most accurate way to describe I-Tech is the way a thoughtful holder once put it: heads you win substantially, tails you lose substantially. Size it like the binary bet it is.
7. Oddity (ODD)
The wildcard, with a warning label (high risk)
What it is
Oddity is a digital-first beauty and wellness company, best known for the IL MAKIAGE makeup brand and the SpoiledChild wellness line. The pitch that made it a market darling: it is a “consumer-tech” company, using data science, machine learning, and computer vision to figure out what a customer wants online and sell it to them directly, cutting out the store. Founded by siblings Oran Holtzman and Shiran Holtzman-Erel and run out of Tel Aviv, it grew fast and printed real profits while doing it.
The numbers today
The stock trades around $12, for a market cap somewhere between $0.6 and $0.8 billion depending on how you count its two share classes. The business itself is impressive on paper: 2025 revenue was about $810 million, up 25%, with net income around $111 million. And yet the chart is a crime scene. The stock hit an all-time high near $79 in June 2025 and has since lost roughly 85% of its value, including a near-50% single-drop in March 2026. Management has been buying back stock into the fall, announcing a $200 million repurchase.
The runway
Global beauty and wellness is a gigantic, durable market, and the direct-to-consumer, data-driven approach is a genuinely different way to attack it. New brands and new categories, including skincare, haircare, supplements, and prescription-grade products, give Oddity adjacent ponds to expand into. If the data-and-brand flywheel is real, the runway is long and wide.
Why it could be a multibagger
This is the deepest-value, highest-variance idea in the group, and that is exactly why it is here. A profitable, fast-growing, founder-led business that has been cut by 85% has enormous upside if the story holds, because you are buying it for a fraction of what the market paid a year ago, with the founders buying back stock alongside you. If the engine is real and the cloud clears, the re-rating could be violent in the good direction.
What has to go right, and what could break it
Read this part twice. Oddity is the riskiest, most controversial name on this list, and I will not dress that up. The crash was triggered by a disclosure around advertising disruption, and it has since been hit with securities class-action lawsuits alleging the company misrepresented its customer-acquisition costs and its dependence on advertising algorithms. Those allegations are unproven, and the company disputes them, but they go to the heart of the bull case: if the “moat” was partly a performance-marketing illusion, then the data-and-AI story is weaker than advertised and the cheap stock is cheap for a reason. There is also plain old consumer-fad risk and a promotional culture. This is a show-me situation with a real credibility overhang. The right way to hold it, if you hold it at all, is small, eyes open, and only because the asymmetry is large enough to justify the genuine chance of being wrong.
“It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price.” — Warren Buffett
Oddity is the name where you have to decide which of those two you are actually looking at.
Important: What this list is, and what it is not
This is not a buy list. It is a research starting point. Five of these seven are small or micro-caps, which means thin trading, wide spreads, and prices that lurch on small news. Two of them, I-Tech and Oddity, are openly binary, where a single regulatory decision or a single lawsuit could decide the outcome.
Price is not the same as value, and I have given you price. Several of these names are not cheap on today’s earnings, even after big falls. A multibagger thesis is a statement about the destination in fifteen to twenty years, not a claim that the current price is a bargain. Two different things. Do not confuse them.
Some of these will not work. The job is to size each one to how confident you actually are, to hold the winners through the drawdowns that are coming, and to make sure no single mistake can hurt you badly. As Munger liked to say, the trick is knowing where you are going to die so you can avoid going there. Run the inversion on every name before you run the dream.
“Time is the friend of the wonderful business.”
— Warren Buffett
The compounding is the point. The list is just where the search starts.
Go deeper
I started a Multibagger Index in February, which has had a strong run lately. That part is for paid members.
→ See the live Multibagger Index here
Not financial advice. This is my own synthesis for my own book. Prices and market caps are approximate, as of early June 2026, and change constantly. I may own positions in names discussed here. Do your own work. I am just a guy on the internet with opinions.
I love these articles because it’s so interesting to see a handful of companies I’ve never even heard of. I was surprised to see Docebo on this list. I had them on my watchlist a while back… maybe I need to revisit that business.